Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) EBITDA (2022 - 2025)

Historic EBITDA for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' EBITDA fell 785.82% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.9 million, marking a year-over-year increase of 28.42%. This contributed to the annual value of -$8.0 million for FY2024, which is 11204.33% down from last year.
  • 60 Degrees Pharmaceuticals' EBITDA amounted to -$2.3 million in Q3 2025, which was down 785.82% from -$1.6 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' EBITDA's 5-year high stood at $4.2 million during Q3 2023, with a 5-year trough of -$4.2 million in Q2 2024.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median EBITDA value was -$2.0 million (recorded in 2023), while the average stood at -$1.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 38773.5% in 2023, then plummeted by 54240.77% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' EBITDA stood at -$1.7 million in 2022, then dropped by 20.37% to -$2.0 million in 2023, then fell by 3.04% to -$2.1 million in 2024, then decreased by 13.29% to -$2.3 million in 2025.
  • Its EBITDA stands at -$2.3 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$1.9 million for Q1 2025.